Hilo de navegación
Melanoma: imagen, genética e inmunología
Publicaciones destacadas
-
High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: a multicenter cohort from the MelaNostrum Consortium
Pellegrini, C; Cardelli, L; Ghiorzo, P; Pastorino, L; Potrony, M;(...)Peris, K; Calista, D; Puig, S; Landi, M T; Fargnoli, M C.Referencia:Journal Of The European Academy Of Dermatology And Venereology 2023.
-
Prognostic role of microsatellites in melanoma and implications in the AJCC classification system: a cohort study
Riquelme-Mc Loughlin, Constanza; Sandoval-Clavijo, Alejandra; de Tord, Maria Blanco; Boada, Aram; Alos, Llucia;(...)Carrera, Cristina; Malvehy, Josep; Puig, Susana; Toll, Agusti; Podlipnik, Sebastian.Referencia:Journal Of The American Academy Of Dermatology 2023.
-
Analysis of dermoscopic changes of blue nevi on digital follow-up: a 21-year retrospective cohort study
Alamon Reig, Francesc; Combalia, Marc; Serra-Garcia, Laura; Albero-Gonzalez, Raquel; Alos, Llucia;(...)Puig-Butille, Joan Anton; Villanueva-Canas, Jose Luis; Puig, Susana; Malvehy, Josep; Podlipnik, Sebastian.Referencia:Journal Of The American Academy Of Dermatology 2023.
-
A reinforcement learning model for AI-based decision support in skin cancer
Barata, Catarina; Rotemberg, Veronica; Codella, Noel C F; Tschandl, Philipp; Rinner, Christoph;(...)Puig, Susana; Rosendahl, Cliff; Soyer, H Peter; Zalaudek, Iris; Kittler, Harald.Referencia:Nature Medicine 2023.
-
The MC1R r allele does not increase melanoma risk in MITF E318K carriers
Wallingford, Courtney K; Demeshko, Anastassia; Krishnakripa, Asha Krishnankutty; Smit, Darren J; Duffy, David L;(...)Law, Matthew H; Cust, Anne E; Potrony, Miriam; Soyer, H Peter; McInerney-Leo, Aideen M.Referencia:British Journal Of Dermatology 2023.
-
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Chesney, JA; Ribas, A; Long, G; Kirkwood, JM; Dummer, R;(...)Chan, EL; Bhatta, S; Gansert, J; Hodi, FS; Gogas, H.Referencia:Journal Of Clinical Oncology 2023.
-
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study
Freites-Martinez A; Nikolaou V; Lallas K; Carrera C; Sollena P;(...)Fattore D; Fabbrocini G; Segura S; Riganti J; Sibaud V .Referencia:Journal Of The American Academy Of Dermatology 2023.
-
Prognostic factors of satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma
Marti-Marti I; Podlipnik S; Cañueto J; Ferrándiz-Pulido C; Deza G;(...)Moreno-Arrones OM; Abril-Pérez C; Tomás-Velázquez A; Sandoval-Clavijo A; Toll A.Referencia:Journal Of The American Academy Of Dermatology 2023.
-
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test
Jarell, Abel; Gastman, Brian R; Hsueh, Eddy C; Podlipnik, Sebastian; Covington, Kyle R;(...)Quick, Ann P; Martin, Brian J; Kurley, Sarah J; Goldberg, Matthew S; Puig, Susana.Referencia:Journal Of The American Academy Of Dermatology 2022.
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M M; Blank, Christian U; Mandala, Mario; Long, Georgina, V; Atkinson, Victoria G;(...)Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline.Referencia:Lancet Oncology 2021.